Norrsken VC announced on November 12, 2026 that it co-led Orakl Oncology’s oversubscribed $34 million Series A alongside Singular, bringing the AI drug-development company’s total funding to $50 million. Orakl plans to expand its dataset and AI research team, increase data generation fivefold and move beyond colorectal and pancreatic cancers into lung and gastric cancers. The proceeds are also intended to establish US and UK teams, deploy predictions across more than 10 drug programs and…
This article has been indexed from Unite.AI
Read the original article:
Orakl Oncology Raises $34M Series A to Expand AI Cancer Drug Prediction